期刊文献+

环孢霉素A治疗22例难治性肾病综合征疗效观察 被引量:5

Treatment of steroid-resistant nephrotic syndrome with cyclosporine:report of 22 cases
暂未订购
导出
摘要 目的探讨环孢霉素A(CsA)治疗难治性肾病(RNS)的疗效。方法对2004年8月~2006年8月收住院的22例RNS患者进行CsA治疗后的临床分析。男12例,女10例,年龄8~45岁,病程4个月~2年。激素依赖12例,激素无效10例。口服CsA3~5mg·kg^-1·d^-1,强的松龙0.1~0.5mg·kg^-1·d^-1和ACEI抑制剂洛丁新5~10mg/d,疗程6~12个月,观察应用CsA前后24h尿蛋白、血脂、肾肝功以及CsA血浓度变化。结果18例(81.8%)患者病情缓解,其中完全缓解14例(63.6%),部分缓解4例(18.1%),无反应4倒(18.1%)。24h尿蛋白定量从治疗前(3.45g±1.51)g下降至(0.862±0.35)g。不良反应有3例恶心、腹泻,4倒多毛症,3例g-龈增生和1例肝功能损害。结论CsA联合中小剂量强的松和ACEI抑制剂治疗RNS是安全和有效的。 Objective To evaluate if CsA is a therapeutic option for refractory nephrotic syndrome(RNS). Methods Twentytwo patients with idiopathic RNS,12 males and 10 females, aged 7-16 years admitted to our hospital from August 2004 to August 2006, received therapy of CsA. The course of their diseases was from 4 months to 2 years. Twelve cases were steroid dependent and 10 were steroid resistant. All patients were treated with CyA (3-5mg · kg^-1·d^-1 ) plus prednisolone(0.1--0.5mg^-1·kg^-1· d^-1) and lotensin(5-10mg/d) for 6 months to 12 months. Results Within 12 months,complete remission was achieved in 14 patients (63.6%) ,partial remission in 4 patients (18.1%) and no response in 4 patients(18.1%), yielding a final response rate of 81.8%. Mean 24h proteinuria declined from 3.45±1.51g before CsA to 0. 862±0. 35g/24h after CsA (P〈0. 001). The adverse effects observed were nephrotoxicity ( 13. 3 % ), hypertrichosis ( 18. 1% ), gingival hyperplasia ( 13.6 % ) and nausea/diarrhea ( 13. 6 % ). Conclusion 12 month therapy with CyA in combination with prednisolone and angiotensin-converting enzyme-inhibitor drugs is effective and safe in treating the patents with refractory nephrotic syndrom.
出处 《重庆医学》 CAS CSCD 2007年第5期417-418,421,共3页 Chongqing medicine
关键词 难治性肾病 环孢霉素A 治疗 cyclosporine A refractory nephrotic syndrome; treatment
  • 相关文献

参考文献11

  • 1Appel GB.Improved outcomes in nephrotic syndrome[J].Cleve Clin J Med,2006,73(2):161
  • 2张玲.加强肾脏科医师对肾脏疾病病理资料重要性的认识[J].重庆医学,2003,32(6):643-643. 被引量:1
  • 3Bloudickova S,Viklicky O.New immunosuppressive agents in chronic progressive glomerulopathies:an update[J].Prague Med Rep,2004,105(3):261
  • 4Fujinaga S,Kaneko K,Muto T,et al.Independent risk factors for chronic cyclosporine induced nephropathy in children with nephrotic syndrome[J].Arch Dis Child,2006,91(8):666
  • 5Rinaldi S,Sesto A,Barsotti P,et al.Cyclosporine therapy monitored with abbreviated area under curve in nephrotic syndrome[J].Pediatr Nephrol,2005,20(1):25
  • 6Radhakrishnan J,Halevy D.Cyclosporin treatment of glomerular diseases[J].Expert Opin Investig Drugs,2000,9(5):1053
  • 7El-Husseini A,El-Basuony F,Mahmoud I,et al.Long-term effects of cyclosporine in children with idiopathic nephrotic syndrome:a single-centre experience[J].Nephrol Dial Transplant,2005,20(11):2433
  • 8Mahmoud I,Basuni F,Sabry A,et al.Single-centre experience with cyclosporin in 106 children with idiopathic focal segmental glomerulosclerosis[J].Nephrol Dial Transplant,2005,20(4):735
  • 9Cattran DC,Appel GB,Hebert LA,et al.Cyclosporine in patients with steroid-resistant membranous nephropathy:a randomized trial[J].Kidney Int,2001,59(4):1484
  • 10Alexopoulos E,Papagianni A,Tsamelashvili M,et al.Induction and long-term treatment with cyclosporine in membranous nephropathy with the nephrotic syndrome[J].Nephrol Dial Transplant,2006,21(11):3127

同被引文献46

引证文献5

二级引证文献82

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部